

**Editor-in-Chief**

Daniel J. George, MD

**Section Editors**

Sanjiv S. Agarwala, MD

Andrew J. Armstrong, MD

Craig M. Kessler, MD

Ursula Matulonis, MD

Susan O'Brien, MD

Mark J. Ratain, MD

Hope S. Rugo, MD

Edward S. Kim, MD

# Rates & Media

## 2026

Indexed through the National Library  
of Medicine (PubMed/MEDLINE),  
PubMed Central (PMC), and EMBASE

Millennium Medical Publishing, Inc.

611 Broadway, Suite 605

New York, NY 10012

Phone: 917.656.7994

[hematologyandoncology.net](http://hematologyandoncology.net)



# EDITORIAL ADVISORY BOARD

## Editor-in-Chief

**Daniel J. George, MD**  
Duke University Medical Center

## Section Editors

### Melanoma in Focus

**Sanjiv S. Agarwala, MD**  
St Luke's Cancer Center and  
Temple University

### Prostate Cancer in Focus

**Andrew J. Armstrong, MD**  
Duke University Medical Center

### Colorectal Cancer in Focus

**Tanios S. Bekaii-Saab, MD**  
Mayo Clinic, Phoenix

### Hematology

**Craig M. Kessler, MD**  
Georgetown University  
Medical School  
Lombardi Comprehensive  
Cancer Center

### Lung Cancer in Focus

**Edward S. Kim, MD**  
City of Hope

### Gynecologic Cancer in Focus

**Ursula Matulonis, MD**  
Dana-Farber Cancer Institute

### Hematologic Malignancies

**Susan O'Brien, MD**  
University of California, Irvine

### Drug Development

**Mark J. Ratain, MD**  
The University of Chicago

### Breast Cancer in Focus

**Hope S. Rugo, MD**  
UCSF Helen Diller Family  
Comprehensive Cancer Center

## Founding Editor

**Bruce D. Cheson, MD**  
The Center for Cancer and Blood  
Disorders

### aHUS, TTP

**Jeffrey C. Laurence, MD**  
Weill Cornell Medicine  
NewYork-Presbyterian  
Hospital

### BREAST CANCER

**Howard A. Burris III, MD**  
The Sarah Cannon  
Cancer Center

**William Gradishar, MD**  
Northwestern University

**Komal Jhaveri, MD**  
Memorial Sloan Kettering  
Cancer Center

**Ruth O'Regan, MD**  
University of Rochester Medical Center

**Lee Schwartzberg, MD**  
University of Nevada

**Sara M. Tolaney, MD**  
Dana-Farber Cancer Institute

### COLORECTAL CANCER

**Edward Chu, MD**  
UPMC Hillman Cancer Center  
University of Pittsburgh

**David H. Ilson, MD, PhD**  
Memorial Sloan Kettering Cancer  
Center

**John L. Marshall, MD**  
Georgetown University Hospital

**Mohamed E. Salem, MD**  
Carolinas Medical Center

**Leonard Saltz, MD**  
Memorial Sloan Kettering  
Cancer Center

### ENDOCRINE CANCER

**Alexandria Phan, MD**  
Medical College of Wisconsin

### GASTROINTESTINAL CANCER

**Farshid Dayyani, MD**  
University of California, Irvine

### GYNECOLOGIC CANCER

**Ursula A. Matulonis, MD**  
Dana-Farber Cancer Center

### HEAD AND NECK CANCER

**Marshall R. Posner, MD**  
Mount Sinai Medical Center

### KIDNEY CANCER

**Robert A. Figlin, MD**  
Cedars-Sinai Comprehensive  
Cancer Center

**Brian I. Rini, MD**  
Vanderbilt University Medical Center

### LEUKEMIA

**Jan A. Burger, MD, PhD**  
MD Anderson Cancer Center

**Richard R. Furman, MD**  
Weill Cornell Medicine  
NewYork-Presbyterian  
Hospital

**Elias Jabbour, MD**  
MD Anderson Cancer Center

**Hagop M. Kantarjian, MD**  
MD Anderson Cancer Center

**Neil E. Kay, MD**  
Mayo Clinic, Rochester

**Jennifer A. Woyach, MD**  
Ohio State University

### LUNG CANCER

**Jeffrey Crawford, MD**  
Duke University Medical Center

**David S. Ettinger, MD**  
The Sidney Kimmel  
Comprehensive Cancer Center  
at Johns Hopkins

**Roy S. Herbst, MD, PhD**  
Yale Cancer Center

**David H. Johnson, MD**  
Southwestern Medical Center

**Corey J. Langer, MD, FACP**  
University of Pennsylvania

### LYMPHOMA

**George P. Canellos, MD**  
Dana-Farber Cancer Institute

**Andre Goy, MD**  
Hackensack University  
Medical Center

**Steven M. Horwitz, MD**  
Memorial Sloan Kettering  
Cancer Center

**Brad S. Kahl, MD**  
Washington University  
School of Medicine

**Craig H. Moskowitz, MD**  
University of Miami  
Sylvester Comprehensive Cancer  
Center

### MELANOMA

**John M. Kirkwood, MD**  
UPMC Hillman Cancer Center

### MULTIPLE MYELOMA

**Kenneth C. Anderson, MD**  
Dana-Farber Cancer Institute

**James R. Berenson, MD**  
Institute for Myeloma  
& Bone Cancer Research

**Sundar Jagannath, MD**  
Mount Sinai Medical Center

**Ola Landgren, MD**  
Sylvester Comprehensive Cancer  
Center

**Paul G. Richardson, MD**  
Dana-Farber Cancer Institute

### MYELOPROLIFERATIVE NEOPLASMS

**Guillermo Garcia-Manero, MD**  
MD Anderson Cancer Center

**Claire Harrison, MD, FRCP**  
Guy's and St Thomas' Hospital

**John O. Mascarenhas, MD**  
Mount Sinai Medical Center

**Srdan Verstovsek, MD, PhD**  
MD Anderson Cancer Center

### OVARIAN CANCER

**Thomas J. Herzog, MD**  
University of Cincinnati Medical  
Center

**Maurie Markman, MD**  
Cancer Treatment Centers  
of America

### PANCREATIC CANCER

**Margaret Tempero, MD**  
University of California,  
San Francisco Comprehensive  
Cancer Center

### PEDIATRIC HEM/ONC

**Mitchell S. Cairo, MD**  
New York Medical College

### PROSTATE CANCER

**Michael A. Carducci, MD**  
The Sidney Kimmel  
Comprehensive Cancer Center  
at Johns Hopkins

### SARCOMAS/GISTS

**George D. Demetri, MD**  
Dana-Farber Cancer Institute

Clinical Advances in

**HEMATOLOGY & ONCOLOGY**<sup>™</sup>  
A Peer-Reviewed Journal

### CEO and Copublisher

Steven H. Kurlander

### President and Copublisher

Paul H. McDaniel

### Editorial Director

Devon Schuyler

### Contributing Editor

Barbara Gormise

### Art Director

Tim Jeffs

### Indexed in PubMed/MEDLINE and EMBASE

**Postmaster:** Please send address changes (form 3579) to *Clinical  
Advances in Hematology & Oncology* c/o DMD, 10255 West  
Higgins Road, Suite 280, Rosemont, IL 60018.

ISSN: 1543-0790 (print), 2996-2447 (online)

## Mission

The mission of *Clinical Advances in Hematology & Oncology* (CAH&O) is to contribute to the advancement of these inter-related fields by providing indispensable editorial content to oncologists, hematologist/oncologists, and pure hematologists. CAH&O fulfills the voiced need of practicing physicians for a practical and readable journal containing the most up-to-date clinical information in malignant and nonmalignant hematologic disorders, as well as solid tumor cancers. CAH&O is also dedicated to being the leader in editorial coverage of targeted therapy.

CAH&O's main editorial departments are:

- Thought leader-driven review articles
- Advances columns featuring engaging interviews with experts on current issues in solid tumor oncology, hematologic malignancies, hematologic disorders, drug development
- Counterpoints: Section addressing clinical controversies in hematology/oncology

## Editorial Direction

A peer-reviewed journal, CAH&O provides editorial content encompassing a wide array of topics relevant and useful to the fields of oncology and hematology, both separately and together. Content is directed by the strong input of experts in the field. CAH&O contains several columns providing cutting edge content on current issues in these fast-moving fields, including:

- In Focus: Breast Cancer, Colorectal Cancer, Chronic Lymphocytic Leukemia, Lung Cancer, Prostate Cancer, Gynecologic Cancer, or Melanoma
- Pro/Con: Experts present their views on controversial issues in hematology and oncology
- Clinical Trials Broadcast: Summaries of ongoing, phase III clinical trials in vital therapeutic areas
- Hem/Onc News: Briefs about the latest developments and global meeting coverage
- Clinical Updates: Peer-reviewed updates on landmark therapeutic developments

## Circulation

*Clinical Advances in Hematology & Oncology* circulates to nearly 29,000 hematology & oncology physicians.

Specialty	Circulation
Colon/Rectal Surgery . . . . .	2,216
Gynecology/Oncology . . . . .	996
Hematology . . . . .	1,254
Hematology/Oncology . . . . .	12,754
Musculo-Skeletal Oncology . . . . .	179
Medical Oncology . . . . .	3,449
Pediatric Hematology/Oncology . . . . .	3,315
Radiation Oncology . . . . .	2,500
Surgical Oncology . . . . .	438
Urology . . . . .	1,700
Other Specialty . . . . .	26
<b>Total Circulation . . . . .</b>	<b>28,827</b>
<i>(As of August 2025)</i>	



## 2026 Print Advertising Rates

**Effective Date:** January 2026

**Agency Commission:** 15% of gross on space, color, and position if paid within 30 days.

**Earned Rate:** Frequency Discounts are earned on the basis of accumulated ad space placed within a 12-month period. All pages of a parent company and its subsidiaries placed in *Clinical Advances in Hematology & Oncology* are combined to determine the earned rate for the publication.

B&W Page Rates	Full Page	2/3 Page	1/2 Page	1/3 Page	1/4 Page
1x	\$4,525	\$3,860	\$3,050	\$2,395	\$1,766
6x	\$4,470	\$3,795	\$2,990	\$2,325	\$1,695
12x	\$4,395	\$3,720	\$2,925	\$2,265	\$1,640
24x	\$4,315	\$3,655	\$2,875	\$2,200	\$1,560
36x	\$4,250	\$3,560	\$2,790	\$2,135	\$1,500
48x	\$4,195	\$3,525	\$2,735	\$2,070	\$1,430
60x	\$4,160	\$3,490	\$2,690	\$2,030	\$1,395
72x	\$4,120	\$3,455	\$2,660	\$1,990	\$1,370
84x	\$4,085	\$3,430	\$2,625	\$1,960	\$1,335
96x	\$4,050	\$3,400	\$2,600	\$1,895	\$1,300
108x	\$4,020	\$3,390	\$2,565	\$1,865	\$1,275
120x	\$3,990	\$3,320	\$2,525	\$1,830	\$1,230

Color Rates*	6-Color	5-Color	4-Color	3-Color	2-Color	Matched PMS	Metallic
	\$3,035	\$2,710	\$2,225	\$2,100	\$995	\$1,050	\$1,380

\* In addition to earned B/W rates; apply to each full or fractional page. No bleed charge.

<b>Inserts</b>	2-page (2x b/w page rate), 4-page (4x b/w page rate), 6-page (6x b/w page rate), 8-page (8x b/w page rate) plus \$800 net insert charge.
<b>BRC's</b>	\$1,770
<b>Cover Tips (supplied)</b>	\$29,500 net (Price based on PITA Pocket Tip w/Folded P.I. inside tips supplied by advertiser to our printer.) \$24,750 net (Price based on single-leaf, 2-sided unbranded tip without P.I. supplied by advertiser to our printer.)

Covers and Premium Rates	Position	B/W Rate Plus
	Cover 4 (2-page minimum)	50%
	Cover 2 (2-page minimum)	25%
	Page opposite 1st Table Contents	20%
	Page opposite 2nd Table of Contents	15%
	Page opposite first editorial page	15%

**List Matching:** A complimentary straight list match for overall results will be performed at the publisher's discretion. Once performed, the client will be responsible for additional file matches by segment, tier, etc., on a per request basis.

**Continuity Discount Program:** Advertise your product in all 8 issues in 2026, and receive a 3% discount on each insertion as placed.

**Cancellation Policy:** 60 days prior for all position contracts and completion of tasks on SOWs.

**Premium Position Cancellation Policy:** Written notice required at least 60 days prior to issue closing date.

## Cover Tips

The cost to run a supplied branded PITA Pocket Cover Tip to the full circulation of *CAH&O* is \$29,300 net.

The cost to run a supplied Cover Tip, standard size 2-page (single leaf, front and back), to the full circulation of *CAH&O* is \$24,750 net. Please see the next page for production specifications. *CAH&O* can accommodate variations in size and dimension and will be quoted on an individual basis from provided samples.

**Bonus Distribution:** The most recent issues of *Clinical Advances in Hematology & Oncology* will be made available to all attendees at the following major oncology meetings:

American Society of Clinical Oncology (March/April and May/June Issues)

American Society of Hematology (November & December Issues)

San Antonio Breast Cancer Symposium (December Issue)

## 2026 Closing Dates

**Issuance:** 8 issues

**Commitment of Space:** 1st of the preceding month (ie, January 1st for the January/February issue).

**Material Due Date:** 15th of the preceding month (ie, January 15th for the January/February issue).

**Insert Due Date:** 20th of the preceding month (ie, January 20th for the January/February issue).

## Ad Sizing (run-a-book ads)

Ad Unit	Trim Size	Bleed	Live Area
<b>2-Page Spread</b>	16 1/4" (width) x 10 7/8" (height)	16 1/2" x 11 1/8" (Bleed should extend 1/8" beyond trim size on all sides)	Maintain 1/4" safety zone for live content inside trim. Allow an extra 1/8" safety for gutter allowance.
<b>Full Page</b>	8 1/8" (width) x 10 7/8" (height)	8 3/8" x 11 1/8" (Bleed should extend 1/8" beyond trim size on all sides)	Maintain 1/4" safety zone for live content inside trim. Allow an extra 1/8" safety for gutter allowance.
<b>Half Page Horizontal</b>	8 1/8" (width) x 5.0" (height)	Ad can bleed on top and sides only. (Extend bleed out 1/8" beyond trim size)	Maintain 1/4" safety zone for live content inside trim
<b>Half Page Vertical</b>	4.0" (width) x 10 7/8" (height)	Ad can bleed on top, bottom, and either into gutter or outer edge. (Extend bleed out 1/8" beyond trim size)	Maintain 1/4" safety zone for live content inside trim. Also, if bleeding into gutter, allow an extra 1/8" for binding.
<b>Quarter Page</b>	4.0" (width) x 5.0" (height)	Ad can bleed on top and gutter or outer edge. (Extend bleed out 1/8" beyond trim size)	Maintain 1/4" safety zone for live content inside trim. Also, if bleeding into gutter, allow an extra 1/8" for binding.

## Cover Tip Specifications:

Trim Size: 7.75" (width) x 4.0" (height). Extend bleed out 1/8" beyond trim. Paper weight: Use 70 lb. or 80 lb.

## Paper Stock

Paper Stock	Body Pages: 45# coated. Covers: 80# coated.
-------------	---

## Specifications for Electronic Files

File Format	<b>Press ready, high res PDF only.</b> (All files and fonts must be embedded; do not save PDF with unlinked OPI data) PDF needs to include crop marks and bleed. Make sure PDF is not set to crop document to frame edges.
-------------	--

## Images/Color/Resolution

4 Color Scans	Resolution should be 2× the screen ruling (and at least 300 dpi). Color should be CMYK.
---------------	---

## Specifications for Printed Inserts **Insert quantity** (includes spoilage allowance): 29,000.

Sizes	2-, 4-, 6-, or 8-page folded supplied inserts. Maximum 8 3/8" and specification.
Insert Trimming	<ul style="list-style-type: none"><li>– The final trim size needs to be 8 3/8" x 11 1/8"</li><li>– Inserts jog to foot. This means that our printer will trim an additional 1/8" from the top. Keep this in mind in your design.</li><li>– Live area: The type should be at least 3/8" from gutter grind, 3/8" from head and 1/4" from face and 1/4" from the foot.</li></ul>
Shipping	<p>Preprinted inserts should be shipped <b>directly to the printer</b> at the address below. Please note the journal name and issue date on your shipment.</p> <p>For contracts or insertion orders, please contact the publisher.</p>

### Publisher

Steve Kurlander or Paul McDaniel  
Millennium Medical Publishing, Inc.  
611 Broadway, Suite 605  
New York, NY 10012  
Tel: 917-656-7994  
e-mail: shk@clinicaladvances.com  
phm@clinicaladvances.com

### Printer

Sheridan  
13487 South Preston Highway  
Lebanon Junction, KY 40150  
Attn: Michael Gladden, H&O, Issue Date

\*Please indicate counts on the packing slip and on each of the cartons

Please send a sample of all shipped inserts to the publisher at the address provided at left.

# Website Banner Ads

## 2025 Average Stats\*

- Average visit duration = 1 minute, 15 seconds
- Average monthly unique visitors = 35,275
- Average monthly visits = 42,856
- Average monthly page views = 50,585
- Average monthly impressions = 74,604
- 18,651 per 25% share of voice (SOV)
- CTR = 0.12%

\*Based on average stats Jan.-June 2025, Google Analytics, WordPress, US only

Hematologyandoncology.net is the online home of the monthly journal, *CAH&O—Clinical Advances in Hematology & Oncology*. Access to the Web site is free for recipients of the print edition of *CAH&O*. Hematologyandoncology.net complements the journal's goal to improve the quality of cancer care by addressing oncology practice for all disease stages and presentations.

## Ad Sizes Available

- Leaderboard (728 × 90)
- Medium Rectangle (300 × 250)
- Mobile Leaderboard (320 × 50)





# Clinical Advances in Hematology & Oncology e-TOCs

## e-TOC Average Stats

- Total distribution: over 22,000 hematology and oncology clinicians
- Average open rate: 20-25%
- Click-to-open rate: 15%
- Delivery Rate: 99.98%

## Two E-mails for Every Issue of CAH&O

e-TOC 1 – “Coming This Month” – delivered two weeks before the printed issue mails

- e-TOC links to [hematologyandoncology.net](http://hematologyandoncology.net)
- Contents of current issue
- Highlights of past issues

e-TOC 2 – “In This Issue” – delivered days before the issue reaches the mailbox

- e-TOC links to [hematologyandoncology.net](http://hematologyandoncology.net)
- Contents of current issue
- Highlights of future issues

## Distribution

Primary Specialty	Sum of Count
Gynecological Oncology (GO)	933
Hematology/Oncology (HO)	13,605
Medical Oncology (ON)	3,582
Musculoskeletal Oncology (OMO)	207
Pediatric Hematology/Oncology (PHO)	3,378
Surgical Oncology (SO)	417
<b>Grand Total</b>	<b>22,122</b>

## Ad Sizes Available

- Leaderboard (728 × 90)
- Medium Rectangle (300 × 250)
- Wide Skyscraper (160 × 600)

Leaderboard (728 × 90)

Clinical Advances in

HEMATOLOGY & ONCOLOGY™

A Peer-Reviewed Journal

[Website](#) | [Archives](#) | [Supplements](#) | [Videos](#) | [MMP Home](#)

Coming in the July Issue of CAH&O

The Effect of Cancer Treatment on Cognitive Function

Asati Kuter, MD, and Jamie S. Myers, PhD, RN, AOCNS

Immunotherapy or Molecularly Targeted Therapy: What Is the Best Initial Treatment for Stage IV BRAF-Mutant Melanoma?

Geoffrey T. Gloney, MD, and Michael B. Atkins, MD

July Columns

Second-Generation ALK Inhibitors

Hiroaki Mano, MD, PhD

The Potential Threat to Blood Transfusion Safety of Emerging Infectious Disease Agents

Susan L. Stramer, PhD

Managing Primary Central Nervous System Lymphoma

Tacy Balchelor, MD, MPH

Stool DNA Testing: A New, Noninvasive Option for Colorectal Cancer Screening

David A. Ahlquist, MD

Highlights in Breast Cancer From the 2015 American Society of Clinical Oncology Annual Meeting

Commentary by Edith A. Perez, MD

Supplements to CAH&O

Novel Management Options for Adult Patients With Progressive Acute Lymphoblastic Leukemia: A Case-Study Compendium

Emerging Data on Multianalyte Algorithm Assays in Breast Cancer: A Clinical Review

New and Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors

New and Emerging Therapeutic Options for Thyroid Carcinoma

New and Emerging Therapeutic Options for the Management of Chemotherapy-Induced Nausea and Vomiting

Managing Risk in Hodgkin Lymphoma

Wide skyscraper (160 × 600)


Stay Connected

[f](#)
[t](#)

Forward To A Friend

Clinical Considerations in Patients With Myelofibrosis

Watch Now ▶



NICHOLAS J. SALLIS, MD, PhD

ClinTopics®

Medium rectangle (300 x 250)

Highlights From Past Issues

Renal Cell Carcinoma in Patients With a Personal or Family History of Hematologic Malignancies

Immunology and Breast Cancer: Toward a New Way of Understanding Breast Cancer and Developing Novel Therapeutic Strategies

Non-Clear Cell Renal Cell Carcinoma, Part 2: Therapy

MET as a Drug Target

New Therapies for Polycythemia Vera


Imaging Techniques for Hepatocellular Carcinoma

The Future of Kidney Cancer Treatment

Intermittent Dosing in Melanoma

Hem/Onc News

Video of the Week



HemOnc TV

TAS-102 vs placebo in patients ≥65 years with mCRC: An age-based analysis of the RECURSE trial

ASCO 2015 - Eric Van Cutsem, MD, PhD, discusses TAS-102 vs placebo in patients over 65 years with metastatic colorectal cancer - an age-based analysis of the RECURSE trial

Phase III RECURSE Trial

Abstract #3595 - TAS-102 vs placebo - an age-based analysis of the RECURSE trial

Abstract #3564 - TAS-102 vs placebo - Geographic Subgroups

Leaderboard (728 × 90)

Millennium Medical Publishing, Inc. | [info@clinicaladvances.com](mailto:info@clinicaladvances.com) | [www.hematologyandoncology.net](http://www.hematologyandoncology.net)

911 Broadway #510

New York, NY 10012

If you no longer wish to receive notifications regarding the most current issue of Clinical Advances in Hematology & Oncology, please click here to unsubscribe. Replies to this message are not monitored or answered.

Copyright © 2015. All Rights Reserved

Millennium Medical Publishing, Inc. | 611 Broadway #310 | New York, NY 10012

8



## Online Advertising Rates & Closing Dates

### CAH&O e-TOC Sponsorship

- Single sponsor = \$8,000 net
- Partial sponsor = \$6,000 net

### Hematologyandoncology.net Advertising Rates

Limited sponsorship program, offered to just four annual sponsors at \$96,000 net per year. Each sponsor will receive approximately 200,000 total yearly impressions. Fully scalable at \$8,000 net/month.

10% discount for print advertising in the same month.

### Digital Cancellations

In accordance with the AAAA/IAB Standard Terms and Conditions for Internet Advertising Version 3.0) found at [http://www.iab.net/media/file/IAB\\_4Asandcs-FINAL.pdf](http://www.iab.net/media/file/IAB_4Asandcs-FINAL.pdf), Advertiser may cancel the I/O as follows:

#### For Flat-Fee or Fixed Placements:

- With minimum of 30 days prior written notice: no penalty
- With less than 30 days prior written notice: Advertiser is responsible for any contracted media to be served within 30 days

Send all digital material to Paul McDaniel at [phm@clinicaladvances.com](mailto:phm@clinicaladvances.com)

### CAH&O e-TOC Closing Dates\*

Email Date	Insertion Order Due	Ad Material Due
1/8/2026	12/19/2025	1/2/2026
1/22/2026	1/8/2026	1/16/2026
2/5/2026	1/22/2026	1/27/2026
2/19/2026	2/5/2026	2/10/2026
3/5/2026	2/19/2026	2/24/2026
3/19/2026	3/5/2026	3/12/2026
4/9/2026	3/26/2026	4/2/2026
4/23/2026	4/9/2026	4/16/2026
5/7/2026	4/23/2026	4/30/2026
5/21/2026	5/7/2026	5/14/2026
6/4/2026	5/21/2026	5/28/2026
6/18/2026	6/4/2026	6/11/2026
7/9/2026	6/25/2026	7/2/2026
7/23/2026	7/9/2026	7/16/2026
8/6/2026	7/23/2026	7/30/2026
8/20/2026	8/6/2026	8/13/2026
9/10/2026	8/27/2026	9/4/2026
9/24/2026	9/10/2026	9/17/2026
10/8/2026	9/24/2026	10/2/2026
10/22/2026	10/8/2026	10/15/2026
11/5/2026	10/22/2026	10/29/2026
11/19/2026	11/16/2026	11/12/2026
12/3/2026	11/19/2026	11/28/2026
12/21/2026	12/10/2026	12/17/2026

\*Dates are subject to change.

## Digital Specifications

Specification	Website	e-TOC
Accepted ad sizes	Leaderboard (728 × 90)	Leaderboard (728 × 90)
	Medium rectangle (300 × 250)	Medium rectangle (300 × 250)
	Mobile leaderboard (320 × 50)	Wide Skyscraper (160 × 600)
Ad expansion available	Yes	N/A
Ad expansion sizes	Leaderboard (728 × 90)	N/A
Ad expansion notes	Ad must require user initiation before expansion. Expanded ad must include clearly visible close controls.	N/A
Ad formats	JPG, GIF, HTML5, third-party served ads	JPG, GIF, animated GIF
Maximum file size	200K	40K
Rich media file size	200K	N/A
Animation time	15 seconds, 3 loops	15 seconds, 3 loops*
Border	All ads with white or partially white background must use a 1-pixel black border	All ads with white or partially white background must use a 1-pixel black border
Third-party click and pixel tracking available?	By Request	By Request
Alternate text required	Yes	Yes
URL	Provide URL for any links	Provide URL for any links

For times when the user's browser does not support creative functionality (i.e. HTML5), provide a standard image file.

\*Please ensure that the first frame of the animated GIF makes sense as a static image.

## Contact

**Advertising:** Paul McDaniel  
phm@clinicaladvances.com  
Tel: (917) 656-7994

**Send all insertion orders to:**  
phm@clinicaladvances.com

Clinical Advances in  
**HEMATOLOGY & ONCOLOGY**<sup>™</sup>  
A Peer-Reviewed Journal

Millennium Medical Publishing, Inc.  
611 Broadway, Suite 605, New York, NY 10012  
Tel: (917) 656-7994 or (914) 720-4485  
hematologyandoncology.net